Autolus Therapeutics (AUTL) Fundamental Analysis: Revenue, Earnings & Valuation

2.82 / 10

Underperform

Fundamentally AUTL rates 2.8/10, indicating weak quality. Positive signals arise from PB‑ROE and Revenue‑MV, yet Asset‑MV and Fixed‑asset turnover are bearish. Revenue growth appears inflated (406% YoY) but other metrics—gross margin (‑39%) and cost‑of‑sales (139%)—are poor, suggesting prudence.

Analysis Checks(6/10)

Revenue-MV

Value-1.20

Score2/3

Weight33.33%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value406.38

Score2/3

Weight-3.28%

1M Return-1.06%

Inventory turnover ratio

Value4.46

Score2/3

Weight-3.82%

1M Return-1.21%

Gross profit margin (%)

Value-39.02

Score1/3

Weight-1.93%

1M Return-0.63%

PB-ROE

Value-0.41

Score2/3

Weight25.71%

1M Return6.97%

Income tax / Total profit (%)

Value-1.63

Score2/3

Weight3.63%

1M Return1.04%

Fixed assets turnover ratio

Value0.88

Score1/3

Weight-3.79%

1M Return-1.24%

Cost of sales ratio (%)

Value139.02

Score1/3

Weight-22.73%

1M Return-9.40%

Asset-MV

Value-0.49

Score1/3

Weight48.73%

1M Return11.07%

Cash-MV

Value-0.09

Score2/3

Weight24.13%

1M Return5.94%

Is AUTL undervalued or overvalued?

AUTL scores 2.82/10 on fundamentals and holds a Premium valuation at present. Backed by its -56.93% ROE, -381.40% net margin, -1.12 P/E ratio, 1.21 P/B ratio, and -25.58% earnings growth, these metrics solidify its Underperform investment rating.